This company listing is no longer active
NTR Stock Overview
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Spectrum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$1.55 |
| 52 Week Low | US$0.26 |
| Beta | 2.14 |
| 11 Month Change | 4.28% |
| 3 Month Change | -1.28% |
| 1 Year Change | 11.63% |
| 33 Year Change | -66.96% |
| 5 Year Change | -94.93% |
| Change since IPO | -67.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.5% | 0.8% | -0.4% |
| 1Y | 11.6% | -16.7% | 7.1% |
Return vs Industry: NTR exceeded the German Biotechs industry which returned -7.1% over the past year.
Return vs Market: NTR exceeded the German Market which returned 6.7% over the past year.
Price Volatility
| NTR volatility | |
|---|---|
| NTR Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NTR's share price has been volatile over the past 3 months.
Volatility Over Time: NTR's weekly volatility has decreased from 18% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 86 | Tom Riga | www.sppirx.com |
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations.
Spectrum Pharmaceuticals, Inc. Fundamentals Summary
| NTR fundamental statistics | |
|---|---|
| Market cap | €191.11m |
| Earnings (TTM) | -€61.65m |
| Revenue (TTM) | €23.43m |
8.2x
P/S Ratio-3.1x
P/E RatioIs NTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTR income statement (TTM) | |
|---|---|
| Revenue | US$25.73m |
| Cost of Revenue | US$2.86m |
| Gross Profit | US$22.87m |
| Other Expenses | US$90.58m |
| Earnings | -US$67.71m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 88.90% |
| Net Profit Margin | -263.16% |
| Debt/Equity Ratio | 107.6% |
How did NTR perform over the long term?
See historical performance and comparison